Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials

Hepatology Research

Volumn 46, Issue 12, 2016, Pages 1226-1233

  Gao, Xiaolin ^a   Zhu, Yu ^a   Wen, Yang ^a   Liu, Guanjian ^a   Wan, Chaomin ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

meta analysis; non alcoholic fatty liver disease; probiotic; randomized controlled trials

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PROBIOTIC AGENT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN BLOOD LEVEL; ITALIAN (CITIZEN); LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION; META ANALYSIS; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPANIARD; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84962396651     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12671     Document Type: Article

References (27)

1. Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem 2011; 22(8): 699–711.
2. Arslan N. Obesity, fatty liver disease and intestinal microbiota. World J Gastroenterol 2014; 20(44): 16452–63.
3. Kelishadi R, Poursafa P. Obesity and air pollution: global risk factors for pediatric non-alcoholic fatty liver disease. Hepat Mon 2011; 11(10): 794–802.
4. Mitchel EB, Lavine JE. Review article: the management of paediatric nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014; 40(10): 1155–70.
5. Endo H, Niioka M, Kobayashi N, Tanaka M, Watanabe T. Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut–liver axis. PLoS One 2013; 8(5) e63388.
6. Lo RS, Austin AS, Freeman JG. Is there a role for probiotics in liver disease? Scientific World Journal 2014; 2014: 874768.
7. Alisi A, Bedogni G, Baviera G et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2014; 39: 1276–85.
8. Wong VW, Won GL, Chim AM et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol 2013; 12(2): 256–62.
9. Malaguarnera M, Vacante M, Antic T et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012; 57: 545–53.
10. Aller R, De Luis DA, Izaola O et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011; 15: 1090–5.
11. Vajro P, Mandato C, Licenziati MR et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011; 52(6): 740–3.
12. Yang W, Wang Y, Yu X, Yang Z. The influence of probiotics medications on nonalcoholic fatty liver disease. Gastroenterol Hepatol 2014; 23(2): 227–9.
13. Jinfeng W, Guoliang Y, Haixia Z, Jiexia D, Shaohua C. Clinical efficacy of bifidobacterium triple active bacteria combined with polyene phosphatidylcholine on NASH. China Modern Doctor 2014; 4(52): 13–5. (published in Chinese).
14. Huixiang Y, Weixiong C, Wei C, Zhu J, Sun Q. Clinical study of probiotics in treatment of non-alcoholic fatty liver disease. Gastroenterology and Liver Disease 2013: 3 (22): 221–3.
15. Yang L, Guo H, Cai J, Cai X, Liu G, Chen D. [Intervention effect ofmicrobiological capsules containing Bacillus subtilis and Enterococcus on intestinal flora in patients with NASH.]. World Chinese J Digestology 2012; 20(20): 1873–8. (In Chinese.).
16. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009; 50(1): 204–10.
17. Gupta R, Bhangoo A, Matthews NA, Anhalt H, Matta Y, Lamichhane B. The prevalence of non-alcoholic fatty liver disease and metabolic syndrome in obese children. J Pediatr Endocrinol Metab 2011; 24(11-12): 907–11.
18. Ma YY1, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2013; 19(40): 6911–8.
19. Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107(5): 450–5.
20. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010; 16(17): 1941–51.
21. Tomita K, Teratani T, Suzuki T et al. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 2014; 59(1): 154–69.
22. Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim Biophys Acta 2015; 1852(9): 1765–78.
23. Bhathena J, Martoni C, Kulamarva A et al. Oral probiotic microcapsule formulation ameliorates non-alcoholic fatty liver disease in Bio F1B Golden Syrian hamsters. PLoS One 2013; 8(3) : e58394.
24. Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology 2012; 55(6): 1738–45.
25. Pacifico L, Bonci E, Andreoli G, Romaggioli S, Di Miscio R, Lombardo CV. Association of serum triglyceride-to-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents. Nutr Metab Cardiovasc Dis 2014; 24(7): 737–43.
26. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37(2): 343–50.
27. Imani Fooladi AA, Mahmoodzadeh Hosseini H, Nourani MR, Khani S, Alavian SM. Probiotic as a novel treatment strategy against liver disease. Hepat Mon 2013; 13(2) : e7521.